Desmethylselegiline - RetinaPharma Technologies

Drug Profile

Desmethylselegiline - RetinaPharma Technologies

Alternative Names: ApoGuard; DES; Desmethyldeprenyl; Neurap; RT-001 - RetinaPharma

Latest Information Update: 20 Jan 2011

Price : $50

At a glance

  • Originator RetinaPharma Technologies; University of Toronto Innovations Foundation
  • Class Antiparkinsonians; Phenethylamines; Small molecules
  • Mechanism of Action Apoptosis inhibitors; Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Age-related macular degeneration; Neurological disorders

Most Recent Events

  • 17 Jan 2005 Desmethylselegiline is available for licensing (http://www.retinapharma.com)
  • 21 Jan 2004 Preclinical trials in Age-related macular degeneration in USA (Unknown route)
  • 21 Jan 2004 Preclinical trials in Neurological disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top